Skip to content

Aripiprazole Lauroxil

Published: July 26, 2026Updated: July 26, 2026

Aripiprazole lauroxil is a long-acting injectable atypical antipsychotic prodrug that is converted to aripiprazole following intramuscular administration. It is used for the treatment of schizophrenia in adults. The medication works through partial agonism at dopamine D2 and serotonin 5-HT1A receptors, with antagonism at 5-HT2A receptors, helping to modulate neurotransmitter activity associated with psychotic symptoms.

Quick summary

Aripiprazole lauroxil is an injectable antipsychotic prodrug used to treat schizophrenia by modulating dopamine and serotonin activity.

Medically reviewed by WellAlly Editorial TeamLast reviewed July 26, 2026Editorial policy
BOXED WARNING

This medication carries a boxed (black box) warning — the strongest type of FDA warning. Review the full prescribing information before use.

Key facts at a glance

RxNorm
1673265
Generic
Aripiprazole Lauroxil
Class
unclassified
Brands
Aristada
Availability
rx
Lactation
unknown
Routes
—
Forms
prefilled syringe
Regions
US, EU, CN, JP
Monitoring
—

This page is for informational purposes only.

Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.

Treatment of schizophrenia in adults, particularly useful for patients who have difficulty adhering to daily oral medications.

Aripiprazole lauroxil is a prodrug that converts to aripiprazole through enzyme-mediated hydrolysis following intramuscular injection. It exerts its effects through partial agonism at dopamine D2 and serotonin 5-HT1A receptors, combined with antagonism at 5-HT2A receptors, helping to stabilize dopamine and serotonin activity in the brain.

This is a long-acting injectable formulation administered every 4-8 weeks. Patients should be monitored for potential side effects including weight gain, metabolic changes, and extrapyramidal symptoms. It is not approved for use in elderly patients with dementia-related psychosis.

Official drug label

WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy